LEGACY Study Showcase

Dr. Roche presents the LEGACY study, which investigated the use of Y-90 glass microspheres for treating early and advanced stage hepatocellular carcinoma (HCC). The study showed that 88% of patients demonstrated a best overall response, with 84% achieving a complete response. Safety in this patient population was also confirmed, with no patients experiencing radiation-induced liver disease or failure. The study concluded that Y-90 glass microspheres are safe and effective in patients with early and advanced stage HCC, with additional explant analysis correlating a minimum threshold dose of 400 Gy to the perfused volume to achieve complete pathologic necrosis.